Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

|<

<

4

5

6

7

8

9

10

11

12

13

14

15

16

17

>

>|

Found 91 Matches

CrohnsDiseasePopulation_V19R1_UniversityOfManchester_20230322

This model is a Crohn's disease (CD) population model for adult patients, created in Simcyp version 19. Alteration of GIT parameters and other physiological parameters like albumin level incorporated based on literature available data of inactive state of CD. The demographic and formulation information are based on the published in vivo pharmacokinetics data of midazolam and budesonide in CD patients. The model details and results are published in 2022 DOI: 10.1007/s40262-022-01169-4 

Osimertinib_V14R1_AstraZeneca_20190717
Compound file from publication: Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label. Pilla Reddy V, Walker M, Sharma P, Ballard P, Vishwanathan K (2018). CPT Pharmacometrics Systems Pharmacolology. doi: 10.1002/psp4.12289.
Fenebrutinib_V19R1_Pfizer_20210804
An optimized Rosuvastatin (V19) model was used and DDIs predominantly driven by gut BCRP inhibition are reasonably recovered. Altogether, the following inhibitors were used: Capmatinib Fenebrutinib Fostamatinib Itraconazole Zepatier The workspace represents the DDI between Rosuvastatin and Fenebrutinib. Notes: - The fuGut in the inhibitor file is set as user input to 1. - An additional systemic clearance of 1.1 L/h is included in the submitted file. Link to the publication with further details: http://doi.org/10.1002/psp4.12672
Rosuvastatin_Itraconazole_OH-Itraconazole_V19R1_Pfizer_20210804
An optimized Rosuvastatin (V19) model was used and DDIs predominantly driven by gut BCRP inhibition are reasonably recovered. Altogether, the following inhibitors were used: Capmatinib Fenebrutinib Fostamatinib Itraconazole Zepatier The workspace represents the DDI between Rosuvastatin and Itraconazole. Link to the publication with further details: http://doi.org/10.1002/psp4.12672

|<

<

4

5

6

7

8

9

10

11

12

13

14

15

16

17

>

>|